2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

tistically significant change in the malignancy rate for the category “non-diagnostic.” These findings are similar to those of Howitt et al. [13] , that is, essentially half of NIFTPs were assigned to the “suspicious for malignancy” category on FNA and had a significant impact on the ma- lignancy rate for the “suspicious for malignancy” catego- ry. Our meta-analysis of the 4 studies showed no signifi- cant heterogeneity for the “non-diagnostic,” “benign,” and “follicular lesion of indeterminate significance” cat- egories of TBSRTC. The heterogeneity between the stud- ies was moderate for the diagnostic category of “follicular neoplasm” and high for the diagnostic categories of “sus- picious for malignancy” and “malignant.” In conclusion, this meta-analysis shows that the risks of malignancy for the TBSRTC system are substantially

altered when NIFTP is considered as a benign entity in histopathologic correlation. These reductions are signifi- cant for the TBSRTC diagnostic categories “benign,” “AUS/FLUS,” “follicular neoplasm,” and “suspicious for malignancy.” The impact is greatest for the AUS/FLUS and “suspicious for malignancy” diagnostic categories. Additional prospective studies will be necessary to deter- mine the precise impact of the histopathologic diagnosis of NIFTP on malignancy rates associated with TBSRTC.

Disclosure Statement The authors have no conflicts of interest to report.

References 1 Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, Abati A: The Nation- al Cancer Institute Thyroid fine needle aspira- tion state of the science conference: a summa- tion. Cytojournal 2008;5:6. 2 Baloch ZW, Seethala RR, Faquin WC, Papo- tti MG, Basolo F, Fadda G, Randolph GW, Hodak SP, Nikiforov YE, Mandel SJ: Nonin- vasive follicular thyroid neoplasm with papil- lary-like nuclear features (NIFTP): a chang- ing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathol 2016;124:616–620. 3 Lloyd RV, Erickson LA, Casey MB, et al: Ob- server variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336–1340. 4 Hirokawa M, Carney JA, Goellner JR, et al: Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 2002;26:1508–1514. 5 Baloch ZW, Shafique K, Flannagan M, Livolsi VA: Encapsulated classic and follicular vari- ants of papillary thyroid carcinoma: compar- ative clinicopathologic study. Endocr Pract 2010;16:952–959. 6 Rivera M, Ricarte-Filho J, Tuttle RM, et al: Molecular, morphologic, and outcome analy- sis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 2010;20: 1085–1093.

13 Howitt BE, Chang S, Eszlinger M, et al: Fine- needle aspiration diagnoses of noninvasive follicular variant of papillary thyroid carcino- ma. Am J Clin Pathol 2015;144:850–857. 14 Maletta F, Massa F, Torregrossa L, et al: Cyto- logical features of “noninvasive follicular thy- roid neoplasmwith papillary-like nuclear fea- tures” and their correlation with tumor his- tology. Hum Pathol 2016;54:134–142. 15 Straccia P, Rossi ED, Bizzarro T, Brunelli C, Cianfrini F, Damiani D, Fadda G: A meta-an- alytic review of the Bethesda System for Re- porting Thyroid Cytopathology: has the rate of malignancy in indeterminate lesions been underestimated? Cancer Cytopathol 2015; 123:713–722. 16 Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analy- ses. BMJ 2003;327:557–560. 17 Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, Chandra A, Co- chand-Priollet B, Fadda G, Hirokawa M, Hong S, Kakudo K, Krane JF, Nayar R, Pa- rangi S, Schmitt F, Faquin WC: The bethesda system for reporting thyroid cytopathology: proposed modifications and updates for the second edition from an international panel. Acta Cytol 2016;60:399–405.

7 Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA: Encapsulated papillary thy- roid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid 2009;19:119–127. 8 Nikiforov YE, Seethala RR, Tallini G, et al: Nomenclature revision for encapsulated fol- licular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016;2:1023– 1029. 9 Poller DN, Baloch ZW, Fadda G, Johnson SJ, Bongiovanni M, Pontecorvi A, Cochand-Pri- ollet B: Thyroid FNA: new classifications and new interpretations. Cancer Cytopathol 2016; 124:457–466. 10 Faquin WC, Wong LQ, Afrogheh AH, et al: Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol 2016;124:181–187. 11 Strickland KC, Howitt BE, Marqusee E, et al: The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of ma- lignancy for fine-needle aspiration diagnostic categories. Thyroid 2015;25:987–992. 12 Canberk S, Gunes P, Onenerk M, Erkan M, Kilinc E, Kocak Gursan N, Kilicoglu GZ: New concept of the encapsulated follicular variant of papillary thyroid carcinoma and its impact on the Bethesda System for Reporting Thy- roid Cytopathology: a single-institute experi- ence. Acta Cytol 2016;60:198–204.

Malignancy Risk and NIFTP

Acta Cytologica 2017;61:187–193 DOI: 10.1159/000469654

134